UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response

Journal of thoracic oncology, 2023-12, Vol.18 (12), p.1615-1617

2023

Volltextzugriff (PDF)

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

Nature medicine, 2019-01, Vol.25 (1), p.111-118

2019

Volltextzugriff (PDF)

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (3), p.546-556

2019

Volltextzugriff (PDF)

What's Old Is New Again: Revisiting Up-Front Chemotherapy in EGFR -Mutated Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2020-01, Vol.38 (2), p.107-110

2020

Volltextzugriff (PDF)

Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib

Journal of thoracic oncology, 2024-02, Vol.19 (2), p.227-239

2024

Volltextzugriff (PDF)

Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non-Small Cell Lung Cancer

Journal of the National Comprehensive Cancer Network, 2024-04, Vol.22 (3)

2024

Volltextzugriff (PDF)

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer

The Journal of clinical investigation, 2022-07, Vol.132 (13)

2022

Volltextzugriff (PDF)

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study

Journal of clinical oncology, 2024-09, Vol.42 (26), p.3105-3114

2024

Volltextzugriff (PDF)

Understanding and targeting resistance mechanisms in NSCLC

Nature reviews. Cancer, 2017-11, Vol.17 (11), p.637-658

2017

Volltextzugriff (PDF)

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study

JTO clinical and research reports, 2023-03, Vol.4 (3), p.100459-100459, Article 100459

2023

Volltextzugriff (PDF)

Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report

Frontiers in oncology, 2024-01, Vol.13, p.1330468-1330468

2024

Volltextzugriff (PDF)

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience

JTO clinical and research reports, 2022-06, Vol.3 (6), p.100328-100328, Article 100328

2022

Volltextzugriff (PDF)

Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

Clinical cancer research, 2020-01, Vol.26 (2), p.439-449

2020

Volltextzugriff (PDF)

Targeted Therapy for Non-Small Cell Lung Cancer: First Line and Beyond

Hematology/oncology clinics of North America, 2023-06, Vol.37 (3), p.575-594

2023

Volltextzugriff (PDF)

Targeted Therapy for Non–Small Cell Lung Cancer

Hematology/oncology clinics of North America, 2023-06, Vol.37 (3), p.575-594

2023

Volltextzugriff (PDF)

Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis

JCO precision oncology, 2020-11 (4), p.1098-1108

2020

Volltextzugriff (PDF)

Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study

JTO clinical and research reports, 2023-10, Vol.4 (10), p.100559-100559, Article 100559

2023

Volltextzugriff (PDF)

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation

Clinical lung cancer, 2019-03, Vol.20 (2), p.e137-e141

2019

Volltextzugriff (PDF)

RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis

Lung cancer (Amsterdam, Netherlands), 2010-12, Vol.70 (3), p.253-262

2010

Volltextzugriff (PDF)

PPD01.07 Phase 2 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination With Nivolumab in Patients With Non-Squamous NSCLC

Journal of thoracic oncology, 2024-07, Vol.19 (7), p.e7-e7

2024

Volltextzugriff (PDF)

CRE24-044: Response to Dabrafenib and Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Metastatic Non-Small Cell Lung Cancer

Journal of the National Comprehensive Cancer Network, 2024-04, Vol.22 (2.5)

2024

Volltextzugriff (PDF)

Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer

Pharmacological reviews, 2013-10, Vol.65 (4), p.1351-1395

2013

Volltextzugriff (PDF)

Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers

Clinical cancer research, 2023-08, Vol.29 (16), p.2979-2987

2023

Volltextzugriff (PDF)

The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC

The oncologist (Dayton, Ohio), 2024-05, Vol.29 (7), p.609-618

2024

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(53)

Sprache

Englisch
(53)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Life Sciences & Biomedicine
(23)
Humans
(19)
Oncology
(19)
Lung Neoplasms - Genetics
(13)
Lung Neoplasms - Drug Therapy
(11)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(10)
Lung Cancer
(10)
Lung Neoplasms - Pathology
(10)
Mutation
(10)
Carcinoma, Non-Small-Cell Lung - Genetics
(9)
Carcinoma, Non-Small-Cell Lung - Pathology
(9)
Animals
(6)
Tumors
(6)
Epidermal Growth Factor Receptors
(5)
Erbb Receptors - Genetics
(5)
Kinases
(5)
Osimertinib
(5)
Respiratory System
(5)
Cell Line, Tumor
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

What's Old Is New Again: Revisiting Up-Front Chemotherapy in EGFR -Mutated Non-Small-Cell Lung Cancer

Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib

Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non-Small Cell Lung Cancer

Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study

Understanding and targeting resistance mechanisms in NSCLC

Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study

Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience

Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

Targeted Therapy for Non-Small Cell Lung Cancer: First Line and Beyond

Targeted Therapy for Non–Small Cell Lung Cancer

Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis

Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation

RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis

PPD01.07 Phase 2 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination With Nivolumab in Patients With Non-Squamous NSCLC

CRE24-044: Response to Dabrafenib and Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Metastatic Non-Small Cell Lung Cancer

Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer

Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers

The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC

Suchergebnisse filtern